Acutaas Chemicals Ltd

- For the Baba deal, Ami Organics will not be raising any significant debt; instead, they will be issuing preferential shares corresponding to the INR68 crore deal value. - There will be minimal cash involvement in the Baba deal. - Current year capex guidance is INR200-220 crores, including the Ankleshwar brownfield project, but no mention of new fundraising for this. - Maintenance capex is INR35 crores, with additional capex planned for solar and electrolyte capacity, to be announced later. - No explicit mention of any other immediate or planned fundraising through debt or equity in the discussion.

- For FY 2024, capex outlay is expected between INR 200 crores to INR 220 crores, including the brownfield project at Ankleshwar. - Greenfield facility capex is around INR 160-170 crores scheduled for this year. - Maintenance capex (excluding electrolyte business) is about INR 35 crores. - Additional capex planned for solar projects though specifics will be announced later. - Electrolyte business capex is anticipated in the second half of FY 2024 once orders increase; exact amount to be announced. - Total capex for the year exceeds INR 200 crores when combining greenfield and other projects. - Capacity expansions ongoing at Unit 3 (Jaghadia) to increase specialty chemicals production by about 15-20%. - Future capex plans depend on order inflows, especially from electrolyte and solar segments.

- The company expects a 25%+ growth in specialty chemicals and 20%-22% growth in the core pharma business (Page 14). - Volume growth, rather than price increases, will drive top-line growth as prices are currently suppressed (Page 16). - The new Ankleshwar greenfield facility, operational by December 2023, will enable 4x volume growth compared to Unit 1 in Surat, supporting FY '24 to FY '26 growth (Pages 10, 17). - Specialty chemical segment aims for 2.5x revenue growth over the next 2-3 years, with several new molecules to be commercialized in FY '24 (Pages 8-9). - Electrolyte additives segment expects initial revenues from H1 FY '24, with a large market opportunity ($2-$3 billion industry) and capacity expansion planned as orders increase (Pages 4,13,17). - Baba Fine Chemicals acquisition anticipates 3-4x growth in revenue in the near term due to new product launches and expanded global market reach (Page 13).

- FY'24 revenue growth expected to continue strongly, driven by advanced pharmaceutical intermediates and specialty chemicals with a 2.5x revenue growth target in 2-3 years. - EBITDA margins improving quarter-on-quarter; currently at 21.9% with sustained margin improvement expected. - PAT margins steady with a 15.8% YoY growth reported for FY'23; further margin expansion likely as high-value contracts mature. - Specialty chemical segment aiming for 18%-19% margins this year, up from previous levels. - Margin expansion is a continuous process; expected 100-150 bps improvement with better volumes and operational efficiencies over FY'24 and FY'25. - New product introductions and long-term contracts (e.g., Fermion) will drive revenue visibility and margin improvement. - Capex for growth (including electrolyte segment) suggests scaling up operations, supporting volume and profitability growth. - Conservative guidance on margin reductions due to new product capacity investments, but overall profitability is expected to improve as volumes grow.

- Several contracts for FY '25 and FY '26 are in line, including in UV absorbers and petrochemicals, with Letters of Intent (LOIs) already signed. - LOIs will be disclosed once they materialize and convert into Memorandums of Understanding (MOUs) in FY '24 and '25. - Specialized contracts including electrolyte additives show progressing orders, with 6 customers approved worldwide and plant-scale trial commercial orders received. - Orders for VCB and FEC electrolyte products are in hand; commercialization expected this year with both domestic and international customers. - Working capital improvements and growing order book support sustained growth. - No specific exact current total order book value mentioned, but positive outlook on conversion of LOIs to firm orders and expected volume growth across segments.